Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

2,647 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Rebox: an adjunct in physical medicine?
Johannsen F, Gam A, Hauschild B, Mathiesen B, Jensen L. Johannsen F, et al. Among authors: jensen l. Arch Phys Med Rehabil. 1993 Apr;74(4):438-40. Arch Phys Med Rehabil. 1993. PMID: 8466428 Clinical Trial.
Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial.
Pieber TR, Deller S, Korsatko S, Jensen L, Christiansen E, Madsen J, Heller SR. Pieber TR, et al. Among authors: jensen l. Diabetes Obes Metab. 2015 Aug;17(8):742-50. doi: 10.1111/dom.12473. Epub 2015 May 20. Diabetes Obes Metab. 2015. PMID: 25855340 Clinical Trial.
The main outcome measure was glucagon concentration at nadir plasma glucose (2.5 mmol/l). Clinical outcomes were also evaluated. ...
The main outcome measure was glucagon concentration at nadir plasma glucose (2.5 mmol/l). Clinical outcomes were also evaluated. ...
Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine.
Madsen JK, Jensen JD, Jensen LW, Pedersen EB. Madsen JK, et al. Among authors: jensen jd, jensen lw. Eur J Clin Pharmacol. 1996;50(3):203-8. doi: 10.1007/s002280050093. Eur J Clin Pharmacol. 1996. PMID: 8737760 Clinical Trial.
Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus.
Mader JK, Jensen L, Ingwersen SH, Christiansen E, Heller S, Pieber TR. Mader JK, et al. Among authors: jensen l. Clin Pharmacokinet. 2016 Nov;55(11):1457-1463. doi: 10.1007/s40262-016-0413-4. Clin Pharmacokinet. 2016. PMID: 27282158 Free PMC article. Clinical Trial.
Inhaled beta 2-agonist and positive expiratory pressure in bronchial asthma. Influence on airway resistance and functional residual capacity.
Christensen EF, Nørregaard O, Jensen LW, Dahl R. Christensen EF, et al. Among authors: jensen lw. Chest. 1993 Oct;104(4):1108-13. doi: 10.1378/chest.104.4.1108. Chest. 1993. PMID: 8404176 Clinical Trial.
Raw decreased with PEP 10 and 15 cm H2O, mean 0.6 (95 percent CI: -1.1, -0.2) and 0.9 (95 percent CI: -1.3, -0.4) cm H2O/L/s. ...
Raw decreased with PEP 10 and 15 cm H2O, mean 0.6 (95 percent CI: -1.1, -0.2) and 0.9 (95 percent CI: -1.3, -0.4) cm H2O/L/s. ...
Multiple doses of pegylated long-acting growth hormone are well tolerated in healthy male volunteers and possess a potential once-weekly treatment profile.
Rasmussen MH, Jensen L, Anderson TW, Klitgaard T, Madsen J. Rasmussen MH, et al. Among authors: jensen l. Clin Endocrinol (Oxf). 2010 Dec;73(6):769-76. doi: 10.1111/j.1365-2265.2010.03863.x. Clin Endocrinol (Oxf). 2010. PMID: 20718773 Clinical Trial.
A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects.
Ikushima I, Jensen L, Flint A, Nishida T, Zacho J, Irie S. Ikushima I, et al. Among authors: jensen l. Adv Ther. 2018 Apr;35(4):531-544. doi: 10.1007/s12325-018-0677-1. Epub 2018 Mar 13. Adv Ther. 2018. PMID: 29536338 Free PMC article. Clinical Trial.
Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes: A randomized, placebo-controlled, double-blind, crossover trial.
Korsatko S, Jensen L, Brunner M, Sach-Friedl S, Tarp MD, Holst AG, Heller SR, Pieber TR. Korsatko S, et al. Among authors: jensen l. Diabetes Obes Metab. 2018 Nov;20(11):2565-2573. doi: 10.1111/dom.13422. Epub 2018 Jul 16. Diabetes Obes Metab. 2018. PMID: 29893488 Free PMC article. Clinical Trial.
The primary endpoint was change in glucagon concentration from target plasma glucose (PG) level 5.5 mmol/L to nadir (target 2.5 mmol/L). ...During the hypoglycaemic clamp from 5.5 mmol/L PG to nadir, the absolute change in mean glucagon concentration was simi …
The primary endpoint was change in glucagon concentration from target plasma glucose (PG) level 5.5 mmol/L to nadir (target 2.5 mmol/ …
The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites.
Jensen JD, Jensen LW, Madsen JK. Jensen JD, et al. Among authors: jensen lw. Eur J Clin Pharmacol. 1994;46(4):333-7. doi: 10.1007/BF00194401. Eur J Clin Pharmacol. 1994. PMID: 7957518
The peak concentration was not significantly different and appeared at around 10 h (Cmax thigh, 175 U.l-1 vs Cmax abdomen, 216 U.l-1). ...
The peak concentration was not significantly different and appeared at around 10 h (Cmax thigh, 175 U.l-1 vs Cmax abdomen, 216 U.l
Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. IV and SC erythropoietin.
Jensen JD, Madsen JK, Jensen LW. Jensen JD, et al. Among authors: jensen lw. Eur J Clin Pharmacol. 1996;50(3):171-7. doi: 10.1007/s002280050088. Eur J Clin Pharmacol. 1996. PMID: 8737755 Clinical Trial.
2,647 results
Jump to page
Feedback